Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Connectivity guided intermittent theta burst stimulation versus repetitive transcranial magnetic stimulation in moderately severe treatment resistant depression›References

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Connectivity guided intermittent theta burst stimulation versus repetitive transcranial magnetic stimulation in moderately severe treatment resistant depression · References

References

CC BY 4.0 · National Institute for Health and Care Research · approximately 27 min read

  1. Morriss R, Webster L, Abdelghani M, Auer DP, Barber S, Bates P, et al.; BRIGhTMIND study team. Connectivity guided theta burst transcranial magnetic stimulation versus repetitive transcranial magnetic stimulation for treatment-resistant moderate to severe depression: study protocol for a randomised double-blind controlled trial (BRIGhTMIND). BMJ Open 2020;10:e038430. 10.1136/bmjopen-2020-038430
  2. Kessler RC, Sampson NA, Berglund P, Gruber MJ, Al-Hamzawi A, Andrade L, et al. Anxious and non-anxious major depressive disorder in the World Health Organization World Mental Health Surveys. Epidemiol Psychiatr Sci 2015;24:210–26.25720357
  3. Word Health Organization. Depression and Other Common Mental Disorders Global Health Estimates. Geneva; 2017.
  4. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. Am J Psychiatry 2006;163:1905–17.17074942
  5. Rizvi SJ, Grima E, Tan M, Rotzinger S, Lin P, McIntyre RS, Kennedy SH. Treatment-Resistant depression in primary care across Canada. Can J Psychiatry 2014;59:349–57.25007419
  6. Balestri M, Calati R, Souery D, Kautzky A, Kasper S, Montgomery S, et al. Socio-demographic and clinical predictors of treatment resistant depression: a prospective European multicenter study. J Affect Disord 2016;189:224–32.26451508
  7. McCrone P, Dhanasiri S, Patel A, Knapp M, Lawton-Smith S. Paying the price: the cost of mental health care in England to 2026. Br J Psychiatry 2008;184:386–92.
  8. Khalid N, Atkins M, Tredget J, Giles M, Champney-Smith K, Kirov G. The effectiveness of electroconvulsive therapy in treatment-resistant depression: a naturalistic study. J ECT 2008;24:141–5.18580559
  9. Ontario HQ. Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis of randomized controlled trials. Ont Health Technol Assess Ser 2016;16:1–66.
  10. Latif A, Nasreldin M, Kader A, Fathy H, Moussa S, Basheer M, et al. A randomized study comparing the short-term neurocognitive outcome of electroconvulsive therapy versus repetitive transcranial magnetic stimulation in the treatment of patients with depression. J Psychiatr Pract 2020;26:23–36.31913967
  11. Serafini G, Pompili M, Belvederi Murri M, Respino M, Ghio L, Girardi P, et al. The effects of repetitive transcranial magnetic stimulation on cognitive performance in treatment-resistant depression. A systematic review. Neuropsychobiology 2015;71:125–39.25925699
  12. Toffanin T, Folesani F, Ferrara M, Belvederi Murri M, Zerbinati L, Caruso R, et al. Cognitive functioning as predictor and marker of response to repetitive transcranial magnetic stimulation in depressive disorders: a systematic review. Gen Hosp Psychiatry 2022;79:19–32.36240649
  13. Martin DM, McClintock SM, Forster JJ, Yan Lo T, Loo CK. Cognitive enhancing effects of rTMS administered to the prefrontal cortex in patients with depression: a systematic review and meta-analysis of individual task effects. Depress Anxiety 2017;34:1029–39.28543994
  14. Fitzgibbon KP, Plett D, Chan BCF, Hancock-Howard R, Coyte PC, Blumberger DM. Cost–utility analysis of electroconvulsive therapy and repetitive transcranial magnetic stimulation for treatment-resistant depression in Ontario. Can J Psychiatry 2020;65:164–73.31801363
  15. Berlim MT, van den Eynde F, Tovar-Perdomo S, Daskalakis ZJ. Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. Psychol Med 2014;44:225–39.23507264
  16. Berlim MT, van den Eynde F, Daskalakis ZJ. Clinically meaningful efficacy and acceptability of low-frequency repetitive transcranial magnetic stimulation (rTMS) for treating primary major depression: a meta-analysis of randomized, double-blind andsham-controlled trials. Neuropsychopharmacol 2013;38:543–51.
  17. NICE. Overview. Repetitive transcranial magnetic stimulation for depression. Guidance. NICE. 2015.
  18. Sehatzadeh S, Daskalakis ZJ, Yap B, Tu HA, Palimaka S, Bowen JM, O’Reilly DJ. Unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant depression: a meta-analysis of randomized controlled trials over 2 decades. J Psychiatry Neurosci 2019;44:151–63.30720259
  19. Larson J, Munkácsy E. Theta-burst LTP. Brain Res 2015;1621:38–50.25452022
  20. Berlim MT, McGirr A, Rodrigues dos Santos N, Tremblay S, Martins R. Efficacy of theta burst stimulation (TBS) for major depression: an exploratory meta-analysis of randomized and sham-controlled trials. J Psychiatr Res 2017;90:102–9.28254709
  21. Chu H, Cheng CM, Liang CS, Chang WH, Juan CH, Huang YZ, et al. Efficacy and tolerability of theta-burst stimulation for major depression: a systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2021;106:110168.33166668
  22. Voigt JD, Leuchter AF, Carpenter LL. Theta burst stimulation for the acute treatment of major depressive disorder: a systematic review and meta-analysis. Transl Psychiatry 2021;11:1–12.33414379
  23. Blumberger DM, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, Giacobbe P, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet 2018;391:1683–92.29726344
  24. Caulfield KA, Fleischmann HH, Cox CE, Wolf JP, George MS, McTeague LM. Neuronavigation maximizes accuracy and precision in TMS positioning: Evidence from 11,230 distance, angle, and electric field modeling measurements. Brain Stimul 2022;15:1192–205.36031059
  25. Fitzgerald PB, Hoy K, McQueen S, Maller JJ, Herring S, Segrave R, et al. A randomized trial of rTMS targeted with MRI based neuro-navigation in treatment-resistant depression. Neuropsychopharmacol 2009;34:1255–62.
  26. Li CT, Cheng CM, Chen MH, Juan CH, Tu PC, Bai YM, et al. Antidepressant efficacy of prolonged intermittent theta burst stimulation monotherapy for recurrent depression and comparison of methods for coil positioning: a randomized, double-blind, sham-controlled study. Biol Psychiatry 2020;87:443–50.31563272
  27. Hebel T, Göllnitz A, Schoisswohl S, Weber FC, Abdelnaim M, Wetter TC, et al. A direct comparison of neuronavigated and non-neuronavigated intermittent theta burst stimulation in the treatment of depression. Brain Stimul 2021;14:335–43.33493624
  28. Bulteau S, Laurin A, Pere M, Fayet G, Thomas-Ollivier V, Deschamps T, et al. Intermittent theta burst stimulation (iTBS) versus 10 Hz high-frequency repetitive transcranial magnetic stimulation (rTMS) to alleviate treatment-resistant unipolar depression: a randomized controlled trial (THETA-DEP). Brain Stimul 2022;15:870–80.35609816
  29. To WT, de Ridder D, Hart J, Vanneste S. Changing brain networks through non-invasive neuromodulation. Front Hum Neurosci 2018;12:128.29706876
  30. Fox MD, Liu H, Pascual-Leone A. Identification of reproducible individualized targets for treatment of depression with TMS based on intrinsic connectivity. Neuroimage 2013;66:151–60.23142067
  31. Sheline YI, Price JL, Yan Z, Mintun MA. Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. Proc Natl Acad Sci USA 2010;107:11020–5.20534464
  32. Hamilton JP, Chen G, Gotlib IH. Investigating neural primacy in major depressive disorder: multivariate Granger causality analysis of resting-state fMRI time-series data. Mol Psychiatry 2011;16:763–72.20479758
  33. Iwabuchi SJ, Peng D, Fang Y, Jiang K, Liddle EB, Liddle PF, Palaniyappan L. Alterations in effective connectivity anchored on the insula in major depressive disorder. Eur Neuropsychopharmacol 2014;24:1784–92.25219936
  34. Cash RFH, Cocchi L, Lv J, Wu Y, Fitzgerald PB, Zalesky A. Personalized connectivity-guided DLPFC-TMS for depression: advancing computational feasibility, precision and reproducibility. Hum Brain Mapp 2021;42:4155–72.33544411
  35. Menon V. Large-scale brain networks and psychopathology: a unifying triple network model. Trends Cogn Sci 2011;15:483–506.21908230
  36. Buckner RL, Andrews-Hanna JR, Schacter DL. The brain’s default network anatomy, function, and relevance to disease. Ann N Y Acad Sci 2009;1124:1–38.
  37. Seeley WW, Menon V, Schatzberg AF, Keller J, Glover GH, Kenna H, et al. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci 2007;27:2349–56.17329432
  38. Fox M, Raichle M. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci 2007;8:700–11.17704812
  39. Anderson RJ, Hoy KE, Daskalakis ZJ, Fitzgerald PB. Repetitive transcranial magnetic stimulation for treatment resistant depression: re-establishing connections. Clin Neurophysiol 2016;127:3394–405.27672727
  40. Iwabuchi SJ, Raschke F, Auer DP, Liddle PF, Lankappa ST, Palaniyappan L. Targeted transcranial theta-burst stimulation alters fronto-insular network and prefrontal GABA. Neuroimage 2017;146:395–403.27651067
  41. Drysdale AT, Grosenick L, Downar J, Dunlop K, Mansouri F, Meng Y, et al. Resting-state connectivity biomarkers define neurophysiological subtypes of depression. Nat Med 2017;23:28–38.27918562
  42. Dinga R, Schmaal L, Penninx BWJH, van Tol MJ, Veltman DJ, van Velzen L, et al. Evaluating the evidence for biotypes of depression: methodological replication and extension of. Neuroimage Clin 2019;22:101796.30935858
  43. Iwabuchi SJ, Auer DP, Lankappa ST, Palaniyappan L. Baseline effective connectivity predicts response to repetitive transcranial magnetic stimulation in patients with treatment-resistant depression. Eur Neuropsychopharmacol 2019;29:681–90.30827757
  44. Fox MD, Buckner RL, White MP, Greicius MD, Pascual-Leone A. Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate. Biol Psychiatry 2012;72:595–603.22658708
  45. Baeken C, Marinazzo D, Wu GR, van Schuerbeek P, de Mey J, Marchetti I, et al. Accelerated HF-rTMS in treatment-resistant unipolar depression: Insights from subgenual anterior cingulate functional connectivity. World J Biol Psychiatry 2014;15:286–97.24447053
  46. Weigand A, Horn A, Caballero R, Cooke D, Stern AP, Taylor SF, et al. Prospective validation that subgenual connectivity predicts antidepressant efficacy of transcranial magnetic stimulation sites. Biol Psychiatry 2018;84:28–37.29274805
  47. Cash RFH, Cocchi L, Lv J, Fitzgerald PB, Zalesky A. Functional magnetic resonance imaging–guided personalization of transcranial magnetic stimulation treatment for depression. JAMA Psychiatry 2021;78:337–9.33237320
  48. Cole EJ, Stimpson KH, Bentzley BS, Gulser M, Cherian K, Tischler C, et al. Stanford accelerated intelligent neuromodulation therapy for treatment-resistant depression. Am J Psychiatry 2020;177:716–26.32252538
  49. Cole EJ, Phillips AL, Bentzley BS, Stimpson KH, Nejad R, Barmak F, et al. Stanford Neuromodulation Therapy (SNT): a double-blind randomized controlled trial. Am J Psychiatry 2022;179:132–41.34711062
  50. Wang WL, Wang SY, Hung HY, Chen MH, Juan CH, Li CT. Safety of transcranial magnetic stimulation in unipolar depression: a systematic review and meta-analysis of randomized-controlled trials. J Affect Disord 2022;301:400–25.35032510
  51. van Lieshout ECC, Jacobs LD, Pelsma M, Dijkhuizen RM, Visser-Meily JMA. Exploring the experiences of stroke patients treated with transcranial magnetic stimulation for upper limb recovery: a qualitative study. BMC Neurol 2020;20:1–13.31900128
  52. Brunoni AR, Chaimani A, Moffa AH, Razza LB, Gattaz WF, Daskalakis ZJ, Carvalho AF. Repetitive transcranial magnetic stimulation for the acute treatment of major depressive episodes: a systematic review with network meta-analysis. JAMA Psychiatry 2017;74:143–52.28030740
  53. Walter G, Martin J, Kirkby K, Pridmore S. Transcranial magnetic stimulation: experience, knowledge and attitudes of recipients. Aust N Z J Psychiatry 2001;35:58–61.11270457
  54. Rosedale M, Lisanby SH, Malaspina D. The structure of the lived experience for persons having undergone rTMS for depression treatment. J Am Psychiatr Nurses Assoc 2009;15:333–7.21659245
  55. Mallon S, Walker K, Bayley Z, Griffiths C. Practitioner perspectives on best practice in non‐treatment factors that support the delivery of repetitive transcranial magnetic stimulation (rTMS) for depression. J Psychiatr Ment Health Nurs 2022;29:463–71.34958704
  56. Clarke M, Lankappa S, Burnett M, Khalifa N, Beer C. Patients with depression who self-refer for transcranial magnetic stimulation treatment: exploratory qualitative study. BJPsych Bull 2018;42:243–7.30056814
  57. McCrone P, Rost F, Koeser L, Koutoufa I, Stephanou S, Knapp M, et al. The economic cost of treatment-resistant depression in patients referred to a specialist service. J Ment Health 2018;27: 567–73.29275697
  58. Morriss R, Garland A, Nixon N, Guo B, James M, Kaylor-Hughes C, et al.; NIHR CLAHRC Specialist Mood Disorder Study Group. Efficacy and cost-effectiveness of a specialist depression service versus usual specialist mental health care to manage persistent depression: a randomised controlled trial. Lancet Psychiatry 2016;3:821–31.27498098
  59. Nguyen KH, Gordon LG. Cost-effectiveness of repetitive transcranial magnetic stimulation versus antidepressant therapy for treatment-resistant depression. Value Health 2015;18:597–604.26297087
  60. Voigt J, Carpenter L, Leuchter A. Cost effectiveness analysis comparing repetitive transcranial magnetic stimulation to antidepressant medications after a first treatment failure for major depressive disorder in newly diagnosed patients – a lifetime analysis. PLOS ONE 2017;12:e0186950.29073256
  61. Simpson KN, Welch MJ, Kozel FA, Demitrack MA, Nahas Z. Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis. Adv Ther 2009;26:346–68.19330495
  62. Mendlowitz AB, Shanbour A, Downar J, Vila-Rodriguez F, Daskalakis ZJ, Isaranuwatchai W, Blumberger DM. Implementation of intermittent theta burst stimulation compared to conventional repetitive transcranial magnetic stimulation in patients with treatment resistant depression: a cost analysis. PLOS ONE 2019;14:e0222546.31513675
  63. Fu Y, Long Z, Luo Q, Xu Z, Xiang Y, Du W, et al. Functional and structural connectivity between the left dorsolateral prefrontal cortex and insula could predict the antidepressant effects of repetitive transcranial magnetic Stimulation. Front Neurosci 2021;15:273.
  64. Taylor SF, Ho SS, Abagis T, Angstadt M, Maixner DF, Welsh RC, Hernandez-Garcia L. Changes in brain connectivity during a sham-controlled, transcranial magnetic stimulation trial for depression. J Affect Disord 2018;232:143–51.29494898
  65. Struckmann W, Bodén R, Gingnell M, Fällmar D, Persson J. Modulation of dorsolateral prefrontal cortex functional connectivity after intermittent theta-burst stimulation in depression: combining findings from fNIRS and fMRI. Neuroimage Clin 2022;34:103028.35537216
  66. Salomons T, Dunlop K, Kennedy SH, Flint A, Geraci J, Giacobbe P, Downar J. Resting-state cortico-thalamic-striatal connectivity predicts response to dorsomedial prefrontal rTMS in major depressive disorder. Neuropsychopharmacol 2014;39:488–98.
  67. Liston C, Chen AC, Zebley BD, Drysdale AT, Gordon R, Leuchter B, et al. Default mode network mechanisms of transcranial magnetic stimulation in depression. Biol Psychiatry 2014;76:517–26.24629537
  68. NCT02016456. TMS Treatment for Depression in the National Health Service. URL: https://clinicaltrials.gov/ct2/show/NCT02016456 (accessed 17 October 2024).
  69. Zhang T, He K, Bai T, Lv H, Xie X, Nie J, et al. Altered neural activity in the reward-related circuit and executive control network associated with amelioration of anhedonia in major depressive disorder by electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry 2021;109:110193.33285263
  70. Philip NS, Barredo J, van ’t Wout-Frank M, Tyrka AR, Price LH, Carpenter LL. Network mechanisms of clinical response to transcranial magnetic stimulation in posttraumatic stress disorder and major depressive disorder. Biol Psychiatry 2018;83:263–72.28886760
  71. Ge R, Downar J, Blumberger DM, Daskalakis ZJ, Vila-Rodriguez F. Functional connectivity of the anterior cingulate cortex predicts treatment outcome for rTMS in treatment-resistant depression at 3-month follow-up. Brain Stimul 2020;13:206–14.31668646
  72. Lüscher C, Malenka RC, Sheng M, Sabatini B, Sü TC. NMDA receptor-dependent long-term potentiation and long-term depression (LTP/LTD). Cold Spring Harb Perspect Biol 2012;4:a005710.22510460
  73. Duman RS, Sanacora G, Krystal JH. Altered connectivity in depression: GABA and glutamate neurotransmitter deficits and reversal by novel treatments. Neuron 2019;102:75–90.30946828
  74. Levitt JG, Kalender G, O’Neill J, Diaz JP, Cook IA, Ginder N, et al. Dorsolateral prefrontal γ-aminobutyric acid in patients with treatment-resistant depression after transcranial magnetic stimulation measured with magnetic resonance spectroscopy. J Psychiatry Neurosci 2019;44:386–94.31199104
  75. Gonsalves MA, White TL, Barredo J, Fukuda AM, Joyce HE, Harris AD, Carpenter LL. Repetitive transcranial magnetic stimulation-associated changes in neocortical metabolites in major depression: a systematic review. Neuroimage Clin 2022;35:103049.35738081
  76. Dubin MJ, Mao X, Banerjee S, Goodman Z, Lapidus KAB, Kang G, et al. Elevated prefrontal cortex GABA in patients with major depressive disorder after TMS treatment measured with proton magnetic resonance spectroscopy. J Psychiatry Neurosci 2016;41:E37–45.26900793
  77. Baeken C, Lefaucheur JP, van Schuerbeek P. The impact of accelerated high frequency rTMS on brain neurochemicals in treatment-resistant depression: Insights from 1H MR spectroscopy. Clin Neurophysiol 2017;128:1664–72.28738276
  78. Spurny-Dworak B, Godbersen GM, Reed MB, Unterholzner J, Vanicek T, Baldinger-Melich P, et al. The impact of theta-burst stimulation on cortical gaba and glutamate in treatment-resistant depression: a surface-based MRSI analysis approach. Front Mol Neurosci. 2022;15:913274.35909445
  79. Trippe J, Mix A, Aydin-Abidin S, Funke K, Benali A. Theta burst and conventional low-frequency rTMS differentially affect GABAergic neurotransmission in the rat cortex. Exp Brain Res 2009;199:411–21.19701632
  80. Stagg CJ, Wylezinska M, Matthews PM, Johansen-Berg H, Jezzard P, Rothwell JC, Bestmann S. Neurochemical effects of theta burst stimulation as assessed by magnetic resonance spectroscopy. J Neurophysiol 2009;101:2872–7.19339458
  81. Mix A, Benali A, Eysel UT, Funke K. Continuous and intermittent transcranial magnetic theta burst stimulation modify tactile learning performance and cortical protein expression in the rat differently. Eur J Neurosci 2010;32:1575–86.20950358
  82. Diederichs C, DeMayo MM, Cole J, Yatham LN, Harris AD, McGirr A. Intermittent theta-burst stimulation transcranial magnetic stimulation increases GABA in the medial prefrontal cortex: a preliminary sham-controlled magnetic resonance spectroscopy study in acute bipolar depression. Front Psychiatry 2021;12:649.
  83. Pszczolkowski S, Cottam WJ, Briley PM, Iwabuchi SJ, Kaylor-Hughes C, Shalabi A, et al. Connectivity-Guided theta burst transcranial magnetic stimulation versus repetitive transcranial magnetic stimulation for treatment-resistant moderate to severe depression: magnetic resonance imaging protocol and SARS-CoV-2–induced changes for a randomized double-blind controlled trial. JMIR Res Protoc 2022;11:e31925. 10.2196/3192535049517
  84. First M, Williams J, Karg R, Spitzer R. Structured Clinical Interview for DSM-5 – Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV). Arlington, VA: American Psychiatric Association; 2015. pp. 1–94.
  85. American Psychiatric Association D, American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, DC: American Psychiatric Association; 2013.
  86. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003;53:649–59.12706951
  87. Williams J, Kobak K, Bech P, Engelhardt N, Evans K, Lipsitz J, et al. The GRID-HAMD: standardization of the Hamilton Depression Rating Scale. Int Clin Psychopharmacol 2008;23:120–9.18408526
  88. Bernstein DP, Stein JA, Newcomb MD, Walker E, Pogge D, Ahluvalia T, et al. Development and validation of a brief screening version of the Childhood Trauma Questionnaire. Child Abuse Negl 2003;27:169–90.12615092
  89. Beck A, Steer R, Brown G. Manual for the Beck Depression Inventory-II. Vol. 2. San Antonio, TX: Psychological Corporation; 1996. pp.13–80.
  90. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606–13.11556941
  91. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003;54:573–83.12946886
  92. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092–7.16717171
  93. Mundt JC, Marks IM, Shear MK, Greist JH. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry 2002;180:461–4.11983645
  94. van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012;15:708–15.22867780
  95. Demyttenaere K, Desaiah D, Petit C, Croenlein J, Brecht S. Patient-assessed versus physician-assessed disease severity and outcome in patients with nonspecific pain associated with major depressive disorder. Prim Care Companion J Clin Psychiatry 2009;11:8–15.19333404
  96. Donders FC. On the speed of mental processes. Acta Psychol (Amst) 1969;30(C):412–31.5811531
  97. Strauss E, Sherman EM, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. Oxford: Oxford University Press; 2006.
  98. Jaeger J. Digit Symbol Substitution Test: the case for sensitivity over specificity in neuropsychological testing. J Clin Psychopharmacol 2018;38:513–19.30124583
  99. Kirchner W. Age differences in short-term retention of rapidly changing information. J Exp Psychol 1958;55:352.13539317
  100. Lovera J, Bagert B, Smoot KH, Wild K, Frank R, Bogardus K, et al. Correlations of perceived deficits questionnaire of multiple sclerosis quality of life inventory with beck depression inventory and neuropsychological tests. J Rehabil Res Dev 2006;43:73–82.16847773
  101. Gallagher P, Nilsson J, Goshawk M, Macritchie K, Lloyd A, Thompson J, et al. Neurocognitive intra-individual variability in mood disorders: effects on attentional response time distributions. Psychol Med 2015;45:2985–97.26073667
  102. Gmehlin D, Fuermaier ABM, Walther S, Debelak R, Rentrop M, Westermann C, et al. Intraindividual variability in inhibitory function in adults with ADHD-An Ex-Gaussian approach. PLOS ONE 2014;9:e112298.25479234
  103. National Institute for Health and Care Excellence. Depression: Management of Depression in Primary and Secondary Care | Guidance | NICE; 2004. URL: www.nice.org.uk/guidance/cg23 (accessed 17 October 2024).
  104. Dalby M, Annas P, Harrison JE; 23andMe Research Team. Further validation of the THINC-it tool and extension of the normative data set in a study of n = 10.019 typical controls. Int J Methods Psychiatr Res 2022;31:e1922.35748111
  105. Gale N, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol 2013;13:1–8.23297754
  106. Nowell LS, Norris JM, White DE, Moules NJ. Thematic analysis: Striving to meet the trustworthiness criteria. Int J Qual Methods 2017;16:160940691773384–13.
  107. Kerr C, Nixon A, Wild D. Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research. Expert Rev Pharmacoecon Outcomes Res 2010;10:269–81.20545592
  108. Lincoln Y, Guba E. Naturalistic Inquiry. Sage; 1985.
  109. NICE. Guide to the Methods of Technology Appraisal 2013 Process and Methods; 2013. URL: www.nice.org.uk/process/pmg9 (accessed 12 February 2023).
  110. Personal Social Services Research Unit (PSSRU). Unit Costs of Health and Social Care. URL: www.pssru.ac.uk/project-pages/unit-costs/ (accessed 13 February 2024).
  111. National Health Service (NHS Improvement). Reference Costs 2020-21; 2022.
  112. GOV.UK. Drugs and Pharmaceutical Electronic Market Information Tool (eMIT). 2022. URL: www.gov.uk/government/publications/drugs-and-pharmaceutical-electronic-market-information-emit (accessed 12 February 2023).
  113. NICE. BNF (British National Formulary). URL: https://bnf.nice.org.uk/ (accessed 12 February 2023).
  114. Royal College of Nursing. NHS Mileage Allowance Rates. URL: www.rcn.org.uk/employment-and-pay/NHS-Employment/NHS-mileage-allowance (accessed 13 February 2023).
  115. Office for National Statistics, Census 2021. Earnings and Working Hours. URL: www.ons.gov.uk/employmentandlabourmarket/peopleinwork/earningsandworkinghours (accessed 12 February 2023).
  116. NICE. Glossary | NICE. URL: www.nice.org.uk/glossary?letter=q (accessed 12 February 2023).
  117. EuroQol. EQ-5D Instruments – EQ-5D. URL: https://euroqol.org/eq-5d-instruments/ (accessed 12 February 2023).
  118. Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ 2018;27:7–22.28833869
  119. Hernández-Alava M, Pudney S. eq5dmap: a command for mapping between EQ-5D-3L and EQ-5D-5L. Stata J 2018;18:395–415. URL: https://euroqol.org/eq-5d-instruments/ (accessed 12 February 2023).
  120. Drummond M, Schulpher M, Claxton K, Stoddart L, Torrance G. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 2015.
  121. Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. PharmacoEcon 2014;32:1157–70.
  122. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med 2010;30:377–99.21225900
  123. Little R, Rubin D. Statistical Analysis with Missing Data. Chichester: John Wiley & Sons; 2019.
  124. Campbell MK, Torgerson DJ. Bootstrapping: estimating confidence intervals for cost-effectiveness ratios. QJM 1999;92:177–82.10326078
  125. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487–96.15497198
  126. Briggs A, Schulpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford: Oxford University Press; 2006.
  127. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779–87.11747057
  128. Mikkelsen M, Barker PB, Bhattacharyya PK, Brix MK, Buur PF, Cecil KM, et al. Big GABA: Edited MR spectroscopy at 24 research sites. Neuroimage 2017;159:32–45.28716717
  129. Andersson JLR, Graham MS, Drobnjak I, Zhang H, Filippini N, Bastiani M. Towards a comprehensive framework for movement and distortion correction of diffusion MR images: Within volume movement. Neuroimage 2017;152:450–66.28284799
  130. Song XW, Dong ZY, Long XY, Li SF, Zuo XN, Zhu CZ, et al. REST: a toolkit for resting-state functional magnetic resonance imaging data processing. PLOS ONE 2011;6:e25031.21949842
  131. McGrath CL, Kelley ME, Holtzheimer PE, Dunlop BW, Craighead WE, Franco AR, et al. Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry 2013;70:821–9.23760393
  132. Fair DA, Cohen AL, Power JD, Dosenbach NUF, Church JA, Miezin FM, et al. Functional Brain Networks Develop from a ‘local to distributed’ organization. PLoS Comput Biol 2009;5:e1000381.19412534
  133. Yeo BT, Krienen FM, Sepulcre J, Sabuncu MR, Lashkari D, Hollinshead M, et al. The organization of the human cerebral cortex estimated by intrinsic functional connectivity. J Neurophysiol 2011;106:1125–65.21653723
  134. Cash RFH, Zalesky A, Thomson RH, Tian Y, Cocchi L, Fitzgerald PB. Subgenual functional connectivity predicts antidepressant treatment response to transcranial magnetic stimulation: independent validation and evaluation of personalization. Biol Psychiatry 2019;86:e5–7.30670304
  135. Jing Y, Zhao N, Deng XP, Feng ZJ, Huang GF, Meng M, et al. Pregenual or subgenual anterior cingulate cortex as potential effective region for brain stimulation of depression. Brain Behav 2020;10:e01591.32147973
  136. Edden RAE, Puts NAJ, Harris AD, Barker PB, Evans CJ. Gannet: a batch-processing tool for the quantitative analysis of gamma-aminobutyric acid–edited MR spectroscopy spectra. J Magn Reson Imaging 2014;40:1445–52.25548816
  137. Maddock RJ, Caton MD, Ragland JD. Estimating glutamate and GLX from GABA-optimized MEGA-PRESS: off-resonance but not diffence spectra values correspond to PRESS values. Psychiatry Res Neuroimaging 2018;279:22–30.30081290
  138. Sedley W, Parikh J, Edden RA, Tait V, Blamire A, Griffiths TD. Human auditory cortex neurochemistry reflects the presence and severity of tinnitus. J Neurosci 2015;35:14822–8.26538652
  139. The BMJ. 11. Correlation and Regression. URL: www.bmj.com/about-bmj/resources-readers/publications/statistics-square-one/11-correlation-and-regression (accessed 12 February 2023).
  140. Bech P, Gram LF, Dein E, Jacobsen O, Vitger J, Bolwig TG. Quantitative rating of depressive states: correlation between clinical assessment, Beck’s Self‐Rating Scale and Hamilton’s Objective Rating Scale. Acta Psychiatr Scand 1975;51:161–70.1136841
  141. Rush AJ, South C, Jain S, Agha R, Zhang M, Shrestha S, et al. Clinically significant changes in the 17-and 6-Item Hamilton Rating Scales for Depression: A STAR*D report. Neuropsychiatr Dis Treat 2021;17:2333–45.34295161
  142. Bauer-Staeb C, Kounali DZ, Welton NJ, Griffith E, Wiles NJ, Lewis G, et al. Effective dose 50 method as the minimal clinically important difference: evidence from depression trials. J Clin Epidemiol 2021;137:200–8.33892086
  143. Hiroe T, Kojima M, Yamamoto I, Nojima S, Kinoshita Y, Hashimoto N, et al. Gradations of clinical severity and sensitivity to change assessed with the Beck Depression Inventory-II in Japanese patients with depression. Psychiatry Res 2005;135:229–35.15996749
  144. Everitt HA, Landau S, O’Reilly G, Sibelli A, Hughes S, Windgassen S, et al.; ACTIB trial group. Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial. Gut 2019;68:1613–23.30971419
  145. Zanini A, Aiello M, Adamo D, Casale S, Cherubino F, Patrona S, et al. Estimation of minimal clinically important difference in EQ-5D Visual Analog Scale Score after pulmonary rehabilitation in subjects with COPD. Respir Care 2015;60:88–95.25336531
  146. Xia, M, Wang J, He Y. BrainNet Viewer: a network visualization tool for human brain connectomics. PLOS ONE 2013;8:e68910. 10.1371/journal.pone.006891023861951
  147. Kaster TS, Downar J, Vila-Rodriguez F, Thorpe KE, Feffer K, Noda Y, et al. Trajectories of response to dorsolateral prefrontal rTMS in major depression: a three-D study. Am J Psychiatry 2019;176:367–75.30764649
  148. Tse NY, Goldsworthy MR, Ridding MC, Coxon JP, Fitzgerald PB, Fornito A, Rogasch NC. The effect of stimulation interval on plasticity following repeated blocks of intermittent theta burst stimulation. Sci Rep 2018;8:1–10.29311619
  149. Gamboa OL, Antal A, Laczo B, Moliadze V, Nitsche MA, Paulus W. Impact of repetitive theta burst stimulation on motor cortex excitability. Brain Stimul 2011;4:145–51.21777874
  150. Nettekoven C, Volz LJ, Kutscha M, Pool EM, Rehme AK, Eickhoff SB, et al. Dose-dependent effects of theta burst and rTMS on cortical excitability and resting-state connectivity of the human motor system. J Neurosci 2014;34:6849–59.24828639
  151. Oliveira-Maia AJ, Press D, Pascual-Leone A. Modulation of motor cortex excitability predicts antidepressant response to prefrontal cortex repetitive transcranial magnetic stimulation. Brain Stimul 2017;10:787–94.28438543
  152. Grammer GG, Kuhle AR, Clark CC, Dretsch MN, Williams KA, Cole JT. Severity of depression predicts remission rates using transcranial magnetic stimulation. Front Psychiatry 2015;6:114.26388786
  153. Hutton TM, Aaronson ST, Carpenter LL, Pages K, West WS, Kraemer C, Sackeim HA. The anxiolytic and antidepressant effects of transcranial magnetic stimulation in patients with anxious depression. J Clin Psychiatry 2023;84:45017.
  154. O’Reardon JP, Solvason HB, Janicak PG, Sampson S, Isenberg KE, Nahas Z, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007;62:1208–16.17573044
  155. Jones BDM, Razza LB, Weissman CR, Karbi J, Vine T, Mulsant LS, et al. Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults: a systematic review and meta-analysis. JAMA Network Open 2021;4:e2125531.34559231
  156. Razza LB, Moffa AH, Moreno ML, Carvalho AF, Padberg F, Fregni F, Brunoni AR. A systematic review and meta-analysis on placebo response to repetitive transcranial magnetic stimulation for depression trials. Prog Neuropsychopharmacol Biol Psychiatry 2018;81:105–13.29111404
  157. Kuehner C. Why is depression more common among women than among men? Lancet Psychiatry 2017;4:146–58.27856392
  158. Office for National Statistics, Census. Suicides in England and Wales. 2021. URL: www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/suicidesintheunitedkingdom/2021registrations (accessed 13 February 2023).
  159. Office for National Statistics, Census 2021. Depression or Anxiety in Adults, Great Britain: 22 September to 3 October 2021. URL: www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/mentalhealth/adhocs/13844depressionoranxietyinadultsgreatbritain 22septemberto3october2021 (accessed 12 February 2023).
  160. Bhui K, Bhugra D, Goldberg D, Sauer J, Tylee A. Assessing the prevalence of depression in Punjabi and English primary care attenders: the role of culture, physical illness and somatic symptoms. Transcult Psychiatry 2004;41:307–22.15551723
  161. Williams ED, Tillin T, Richards M, Tuson C, Chaturvedi N, Hughes AD, Stewart R. Depressive symptoms are doubled in older British South Asian and Black Caribbean people compared with Europeans: associations with excess co-morbidity and socioeconomic disadvantage. Psychol Med 2015;45:1861–71.25677948
  162. Smaje C, le Grand J. Ethnicity, equity and the use of health services in the British NHS. Soc Sci Med 1997;45:485–96.9232742
  163. Dhamne SC, Kothare RS, Yu C, Hsieh TH, Anastasio EM, Oberman L, et al. A measure of acoustic noise generatedfrom transcranial magnetic stimulation coils. Brain Stimul 2014;7:432–4.24582370
  164. Koponen LM, Goetz SM, Tucci DL, Peterchev A. Sound comparison of seven TMS coils at matched stimulation strength. Brain Stimul 2020;13:873–80.32289720
  165. Rossi S, Antal A, Bestmann S, Bikson M, Brewer C, Brockmöller J, et al.; basis of this article began with a Consensus Statement from the IFCN Workshop on ‘Present, Future of TMS: Safety, Ethical Guidelines’, Siena, October 17-20, 2018, updating through April 2020. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clin Neurophysiol 2021;132:269–306.33243615
  166. Florentine M, Ren Buus S, Poulsen T. Temporal integration of loudness as a function of level. J Acoust Soc Am 1996;99:669.
  167. Borckardt JJ, Nahas ZH, Teal J, Lisanby SH, McDonald WM, Avery D, et al. The painfulness of active, but not sham, transcranial magnetic stimulation decreases rapidly over time: results from the double-blind phase of the OPT-TMS Trial. Brain Stimul 2013;6:925–8.23769413
  168. Cotovio G, Oliveira-Maia AJ, Paul C, Faro Viana F, Rodrigues da Silva D, Seybert C, et al. Day-to-day variability in motor threshold during rTMS treatment for depression: clinical implications. Brain Stimul 2021;14:1118–25.34329797
  169. Vallejo-Torres L, Castilla I, González N, Hunter R, Serrano-Pérez P, Perestelo-Pérez L. Cost-effectiveness of electroconvulsive therapy compared to repetitive transcranial magnetic stimulation for treatment-resistant severe depression: a decision model. Psychol Med 2015;45:1459–70.25354790
  170. Drevets WC, Savitz J, Trimble M. The subgenual anterior cingulate cortex in mood disorders. CNS Spectr 2008;13:663–81.18704022
  171. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, et al. Deep brain stimulation for treatment-resistant depression. Neuron 2005;45:651–60.15748841
  172. Hopman HJ, Chan SMS, Chu WCW, Lu H, Tse CY, Chau SWH, et al. Personalized prediction of transcranial magnetic stimulation clinical response in patients with treatment-refractory depression using neuroimaging biomarkers and machine learning. J Affect Disord 2021;290:261–71.34010751
  173. Kaiser RH, Andrews-Hanna JR, Wager TD, Pizzagalli DA. Large-scale network dysfunction in major depressive disorder: a meta-analysis of resting-state functional connectivity. JAMA Psychiatry 2015;72:603–11.25785575
  174. Kelly AM, Uddin LQ, Biswal BB, Castellanos FX, Milham MP. Competition between functional brain networks mediates behavioral variability. Neuroimage 2008;39:527–37.17919929
  175. Keller JB, Hedden T, Thompson TW, Anteraper SA, Gabrieli JDE, Whitfield-Gabrieli S. Resting-state anticorrelations between medial and lateral prefrontal cortex: association with working memory, aging, and individual differences. Cortex 2015;64:271–80.25562175
  176. Austin MP, Mitchell P, Goodwin GM. Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry 2001;178:200–6.11230029
  177. McDermott LM, Ebmeier KP. A meta-analysis of depression severity and cognitive function. J Affect Disord 2009;119:1–8.19428120
  178. McIntyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, Gallaugher LA, Kudlow P, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates and treatment interventions. Depress Anxiety 2013;30:515–27.23468126
  179. Dhami P, Moreno S, Croarkin PE, Blumberger DM, Daskalakis ZJ, Farzan F. Baseline markers of cortical excitation and inhibition predict response to theta burst stimulation treatment for youth depression. Sci Rep 2023;13:19115.37925557
  180. Abdallah CG, Niciu MJ, Fenton LR, Fasula MK, Jiang L, Black A, et al. Decreased occipital cortical glutamate levels in response to successful cognitive-behavioral therapy and pharmacotherapy for major depressive disorder. Psychother Psychosom 2014;83:298–307.25116726
  181. Mullins PG, McGonigle DJ, O’Gorman RL, Puts NA, Vidyasagar R, Evans CJ, Edden RA; Cardiff Symposium on MRS of GABA. Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA. Neuroimage 2014;86:43–52.23246994
  182. Lee Y, Ragguett RM, Mansur RB, Boutilier JJ, Rosenblat JD, Trevizol A, et al. Applications of machine learning algorithms to predict therapeutic outcomes in depression: a meta-analysis and systematic review. J Affect Disord 2018;241:519–32.30153635
  183. Denegri S, Coldham T, Eglin S, Frost R, Kerridge L, Matthews R. Going the Extra Mile: Improving the Nation’s Health and Wellbeing Through Public Involvement in Research. London: NIHR; 2015.
  184. Seeralan T, Härter M, Koschnitzke C, Scholl M, Kohlmann S, Lehmann M, et al. Patient involvement in developing a patient-targeted feedback intervention after depression screening in primary care within the randomized controlled trial GET.FEEDBACK.GP. Health Expect 2021;24:95–112.
  185. Crocker JC, Ricci-Cabello I, Parker A, Hirst JA, Chant A, Petit-Zeman S, et al. Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis. Br Med J 2018;363:k4738.30487232
  186. Staley K. Exploring Impact. Public Involvement in NHS, Public Health and Social Care Research. Eastleigh: INVOLVE; 2009.
  187. Kearney A, Williamson P, Young B, Bagley H, Gamble C, Denegri S, et al. Priorities for methodological research on patient and public involvement in clinical trials: a modified Delphi process. Health Expect 2017;20:1401–10.28618076
  188. Jennings H, Slade M, Bates P, Munday E, Toney R. Best practice framework for Patient and Public Involvement (PPI) in collaborative data analysis of qualitative mental health research: Methodology development and refinement. BMC Psychiatry 2018;18:1–11.
  189. Evans D, Coad J, Cottrell K, Dalrymple J, Davies R, Donald C, et al. Public involvement in research: assessing impact through a realist evaluation. Health Serv Deliv Res 2014;2:1–128.
  190. Price A, Albarqouni L, Kirkpatrick J, Clarke M, Liew SM, Roberts N, Burls A. Patient and public involvement in the design of clinical trials: an overview of systematic reviews. J Eval Clin Pract 2018;24:240–53.29076631
  191. Lobban F, Dodd AL, Sawczuk AP, Asar O, Dagnan D, Diggle PJ, Griffiths M, Honary M, Knowles D, Long R, Morriss R, Parker R, Jones S. Assessing Feasibility and Acceptability of Web-Based Enhanced Relapse Prevention for Bipolar Disorder (ERPonline): A Randomized Controlled Trial. J Med Internet Res 2017;19:e85.28341619
  192. Lee JC, Blumberger DM, Fitzgerald PB, Daskalakis ZJ, Levinson AJ. The role of transcranial magnetic stimulation in treatment-resistant depression: a review. Curr Pharm Des 2012;18:5846–52.22681165
  193. Cleare A, Pariante C, Young A, et al. Evidenced-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association Psychopharmacology guidelines. J Psychopharmacol 2015;29:459–525.25969470
  194. Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CH. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 2013;74:1101–7.24330897
  195. Tundo A, de Filippis R, De Crescenzo F. Pramipexole in the treatment of unipolar and bipolar depression. A systematic review and meta-analysis. Acta Psychiatr Scand 2019;140:116–25.31111467
  196. Brown S, Rittenbach K, Cheung S, McKean G, MacMaster FP, Clement F. Current and Common Definitions of Treatment-Resistant Depression: Findings from a Systematic Review and Qualitative Interviews. Can J Psychiatry 2019;64(6):380–7. 10.1177/070674371982896530763119
  197. McAllister-Williams RH, Anderson IM, Finkelmeyer A, Gallagher P, Grunze HC, Haddad PM, et al. Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial. Lancet Psychiatry 2016;3:117–27. 10.1016/S2215-0366(15)00436-826727041
  198. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal 2013. 2013; NICE article [PMG9]. URL: www.nice.org.uk/article/pmg9/chapter/Foreword
  199. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–36. 10.1007/s11136-0119903x21479777
  200. Curtis LA, Burns A. Unit Costs of Health & Social Care 2020. Unit Costs of Health and Social Care; 2020. 10.22024/UniKent/01.02.84818
  201. NHS England. 2020/21 National cost collection data publication. URL: www.england.nhs.uk/publication/2020-21-national-cost-collection-data-publication (accessed 18/11/2024).
  202. Mattke S, Balakrishnan A, Bergamo G, Newberry SJ. A review of methods to measure health-related productivity loss. Am J Manag Care 2007;13:211–7.17408341
  203. Nicholson S, Pauly MV, Polsky D, Sharda C, Szrek H, Berger ML. Measuring the effects of work loss on productivity with team production. Health Econ 2006;15:111–23. 10.1002/hec.105216200550
  204. Office for National Statistics. Dataset: Earnings and Hours Worked, All Employees: ASHE Table 1. 2020. URL: www.ons.gov.uk/employmentandlabourmarket/peopleinwork/earningsandworkinghours/datasets/allemployeesashetable1 (accessed 26 March 2021).
  205. White IR, Horton NJ, Carpenter J, Pocock SJ. Strategy for intention to treat analysis in randomised trials with missing outcome data. Br Med J (Clinical research ed.) 2011a;342:d40.
  206. Royston P, White IR. Multiple imputation by chained equations (MICE): implementation in Stata. J Stat Softw 2011;45:1–20.
  207. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011b;30:37.
  208. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 2002;11:415–30. 10.1002/hec.67812112491
  209. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al.; CHEERS Task Force. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Br Med J (Clinical research ed.) 2013;346:f1049.
  210. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al.; CHEERS 2022 ISPOR Good Research Practices Task Force. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Br Med J (Clinical research ed.) 2022;376:e067975.
← Patient and public involvementAdditional information →

Attribution. Richard Morriss; Lucy Webster; Luke Ingram; Mohamed Abdelghani; Adriana Anton; Shaun Barber et al. (2025). Connectivity guided intermittent theta burst stimulation versus repetitive transcranial magnetic stimulation in moderately severe treatment resistant depression. National Institute for Health and Care Research. Copyright © 2025 Morriss et al. Licensed under CC BY 4.0. NCBI Bookshelf NBK612327. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support